The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-
To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir.
| Condition(s) | HIV/AIDS |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | To study the safety and effectiveness of CAR-T Cell therapy on HIV patients whose plasma HIV has been successfully suppressed after cART, which is expected to enhance the res-constitution of HIV-specific immune function to assist the eradication of HIV reservoir. |
| Who can participate | Inclusion Criteria: 1. HIV infection confirmed. 2. Receiving cART more than 12 months. 3. HIV viral-load \< 50 copies/ml and CD4 cell count more than 350 cells/ul. 4. Without serious liver, heart, liver and kidney diseases. 5. The subjects know about the study and volunteer to attend the research and sign the informed consent. Exclusion Criteria: 1. With active HBV or HCV infection, or serious opportunistic infections. 2. With serious chronic disease such like diabetes, the mental illness,et al 3. History of suffering from pancreatitis during cART. 4. Pregnant or breast-fed. 5. With poor adherence. 6. Unable to complete follow up. |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Lead sponsor | Guangzhou 8th People's Hospital |
| Locations | Guangzhou, Guangdong, China |
| Start date | 2017-10-04 |
| NCT ID | NCT03240328 |
| Official listing | https://clinicaltrials.gov/study/NCT03240328 |